CA2091253A1 - Method for inhibiting the infectivity of human immunodeficiency virus - Google Patents
Method for inhibiting the infectivity of human immunodeficiency virusInfo
- Publication number
- CA2091253A1 CA2091253A1 CA 2091253 CA2091253A CA2091253A1 CA 2091253 A1 CA2091253 A1 CA 2091253A1 CA 2091253 CA2091253 CA 2091253 CA 2091253 A CA2091253 A CA 2091253A CA 2091253 A1 CA2091253 A1 CA 2091253A1
- Authority
- CA
- Canada
- Prior art keywords
- gpl20
- antibodies
- lymphocytes
- hiv
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 17
- 230000007910 cell fusion Effects 0.000 claims abstract description 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 10
- 230000002163 immunogen Effects 0.000 claims abstract description 8
- 230000027455 binding Effects 0.000 claims description 71
- 210000004698 lymphocyte Anatomy 0.000 claims description 49
- 230000003053 immunization Effects 0.000 claims description 37
- 238000002649 immunization Methods 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 7
- 230000009545 invasion Effects 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 32
- 230000004927 fusion Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 238000003556 assay Methods 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 208000031886 HIV Infections Diseases 0.000 description 9
- 208000037357 HIV infectious disease Diseases 0.000 description 9
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 7
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 230000003302 anti-idiotype Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 210000004201 immune sera Anatomy 0.000 description 3
- 229940042743 immune sera Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000087624 Monoclona Species 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960000587 glutaral Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58972290A | 1990-09-28 | 1990-09-28 | |
| US589,722 | 1990-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2091253A1 true CA2091253A1 (en) | 1992-03-29 |
Family
ID=24359218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2091253 Abandoned CA2091253A1 (en) | 1990-09-28 | 1991-08-26 | Method for inhibiting the infectivity of human immunodeficiency virus |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0550516A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU653366B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2091253A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1992005799A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69227112D1 (de) * | 1991-07-16 | 1998-10-29 | Transmed Biotech Inc | Verfahren und zusammensetzungen für die gleichzeitige analyse einer vielzahl von analyten |
| CA2152915A1 (en) * | 1992-12-31 | 1994-07-21 | Jonathan M. Gershoni | Antibodies directed against binding-associated epitopes |
| DE69428896T2 (de) | 1993-05-07 | 2002-06-20 | Akzo Nobel N.V., Arnheim/Arnhem | Hiv immunogene komplexe |
| EP0774000A1 (en) * | 1994-07-19 | 1997-05-21 | Beth Israel Hospital | Antibodies that bind a conformationally altered cd4 molecule induced upon human immunodefficiency virus binding |
| EP0903860A1 (en) | 1997-09-17 | 1999-03-24 | Matsushita Electric Industrial Co., Ltd. | PLL frequency synthesizer |
| EP1141315B1 (en) | 1998-12-31 | 2008-01-23 | Novartis Vaccines and Diagnostics, Inc. | Modified hiv env polypeptides |
| CA2360347C (en) | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| WO2000039304A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| DK1137786T3 (da) * | 1999-10-08 | 2007-08-06 | Univ Maryland Biotech Inst | Viruscoatprotein/receptorkimærer og fremgangsmåder til brug heraf |
| US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| US6908612B2 (en) | 1999-10-08 | 2005-06-21 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| FR2799974B1 (fr) * | 1999-10-25 | 2001-11-30 | Aventis Pasteur | Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih |
| EP2412242A3 (en) | 2001-07-05 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2591227B1 (fr) * | 1985-12-06 | 1988-11-10 | Pasteur Institut | Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications |
| WO1988009181A2 (en) * | 1987-05-29 | 1988-12-01 | Tanox Biosystems, Inc. | Monoclonal antibodies neutralizing hiv-1 |
| US4908203A (en) * | 1987-09-09 | 1990-03-13 | Johnson & Johnson | Method for inducing HIV neutralizing antibodies using an internal image idiotope |
-
1991
- 1991-08-26 EP EP91916608A patent/EP0550516A1/en not_active Withdrawn
- 1991-08-26 AU AU86317/91A patent/AU653366B2/en not_active Ceased
- 1991-08-26 WO PCT/US1991/006079 patent/WO1992005799A1/en not_active Ceased
- 1991-08-26 CA CA 2091253 patent/CA2091253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU653366B2 (en) | 1994-09-29 |
| WO1992005799A1 (en) | 1992-04-16 |
| AU8631791A (en) | 1992-04-28 |
| EP0550516A1 (en) | 1993-07-14 |
| EP0550516A4 (cg-RX-API-DMAC7.html) | 1994-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Celada et al. | Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. | |
| Chanh et al. | Monoclonal anti-idiotypic antibody mimics the CD4 receptor and binds human immunodeficiency virus. | |
| US6057421A (en) | Variable heavy and light chain regions of murine monoclonal antibody 1F7 | |
| AU653926B2 (en) | HIV-1 ENV fragment fusion protein | |
| US5854400A (en) | Monoclonal antibodies which neutralize HIV-1 infection | |
| NZ228869A (en) | Hiv peptides, antibodies and vaccines | |
| AU653366B2 (en) | Method for inhibiting the infectivity of human immunodeficiency virus | |
| CA2066607A1 (en) | Peptides associated with the cd4 binding region of gp120 and their methods of use | |
| EP0492560B1 (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of HIV-1, and related peptides | |
| US6008044A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC) | |
| US5516895A (en) | Antibodies specific towards gp 48 | |
| WO1993023427A1 (en) | Hiv protein epitopes immunologically homologous to hla | |
| WO1992015885A1 (en) | Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations | |
| IE920785A1 (en) | Methods for selecting antibody reagents; anti-idiotype¹antibodies; and aids vaccine formulations | |
| Sugano et al. | Human monoclonal antibody against glycoproteins of human immunodeficiency virus | |
| US6083504A (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1) | |
| JP2583555B2 (ja) | ヒト免疫不全ウイルス（ｈｉｖ）の検出と治療のための方法および物質 | |
| WO1989010416A1 (en) | PROTECTIVE PEPTIDES DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUS-1 gp160 | |
| JP4423374B2 (ja) | Ｈｉｖ−２型ヒトレトロウイルスのトランスメンブランエンベロープ糖タンパク質の抗原、及び、該抗原に免疫類似性を有する抗原 | |
| KR920001772B1 (ko) | 포유류 중의 HIV-억제 항체 유도성 사람 면역 결핍 바이러스(HIV) env-암호화된 펩타이드 | |
| EP0512023A1 (en) | Medicaments and methods for treating aids and arc employing anti-carbohydrate antibodies and carbohydrate antigens | |
| JP2007534615A (ja) | Ｈｉｖ免疫原性複合体 | |
| EP0717847B1 (en) | Use of antibodies against beta-2 microglobulin-free, class i hla molecules to provide hiv diagnostic tests as well as compositions having a protective action against hiv infections | |
| WO1990000617A1 (en) | Antibodies specific towards gp 48 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |